These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38116588)

  • 1. Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
    Botros A; Rival PM; Page F; Davis ID; Sengupta S
    BJU Int; 2024 Apr; 133 Suppl 4():7-10. PubMed ID: 38116588
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Fukushima H
    Int J Urol; 2023 Dec; 30(12):1120-1121. PubMed ID: 37740488
    [No Abstract]   [Full Text] [Related]  

  • 3. A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer.
    Lichtbroun B; Srivastava A; Ghodoussipour S
    Eur Urol Focus; 2023 Jul; 9(4):557-558. PubMed ID: 37270358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
    Arai T; Sazuka T; Sato H; Imamura Y; Sakamoto S; Ichikawa T
    Int J Urol; 2022 Oct; 29(10):1238-1240. PubMed ID: 35726052
    [No Abstract]   [Full Text] [Related]  

  • 5. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
    Stenzl A; Rouprêt M; Witjes JA; Gontero P
    Eur Urol; 2023 Mar; 83(3):193-194. PubMed ID: 36473782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    Montorsi F; Moschini M; Gandaglia G; Briganti A
    J Urol; 2024 Mar; 211(3):482-483. PubMed ID: 38329052
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter to the editor regarding the article 'Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
    Besiroglu H
    BJU Int; 2023 Jul; 132(1):112. PubMed ID: 36896889
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Nishimura N; Miyake M; Nakahama T; Miyamoto T; Nishimoto K; Oyama M; Matsushita Y; Miyake H; Fukuhara H; Inoue K; Kobayashi K; Matsumoto H; Matsuyama H; Fujii T; Hirao Y; Fujimoto K
    Int J Urol; 2023 Dec; 30(12):1112-1119. PubMed ID: 37605814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A Hands-on Guide Through the Energy Landscape.
    Nicoletti R; Gauhar V; Castellani D; Enikeev D; Herrmann TRW; Teoh JY
    Eur Urol Focus; 2023 Jul; 9(4):567-570. PubMed ID: 37179226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Miyake M; Nishimura N; Fujii T; Fujimoto K
    Int J Urol; 2023 Nov; 30(11):944-957. PubMed ID: 37522629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
    Richards KA; Smith ND; Steinberg GD
    J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
    Yanagisawa T; Kawada T; von Deimling M; Bekku K; Laukhtina E; Rajwa P; Chlosta M; Pradere B; D'Andrea D; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
    Eur Urol Focus; 2024 Jan; 10(1):41-56. PubMed ID: 37495458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour.
    Suarez-Ibarrola R; Soria F; Abufaraj M; D'Andrea D; Preto M; Gust KM; Briganti A; Shariat SF; Gontero P
    BJU Int; 2019 Apr; 123(4):646-650. PubMed ID: 30248235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstaging after Transurethral Resection of the Bladder for Non-Muscle-Invasive Cancer of the Bladder: Who Is at Highest Risk?
    Volz Y; Trappmann R; Ebner B; Eismann L; Enzinger B; Hermans J; Pyrgidis N; Stief C; Schulz GB
    Urol Int; 2024; 108(1):42-48. PubMed ID: 37944501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
    Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
    Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Tellini R; Mari A; Minervini A
    Int J Urol; 2022 Jul; 29(7):640. PubMed ID: 35384083
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Hayakawa N; Kikuchi E
    Int J Urol; 2022 Jul; 29(7):639-640. PubMed ID: 35368133
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Naselli A; Pirola GM
    Int J Urol; 2022 Jul; 29(7):638-639. PubMed ID: 35362114
    [No Abstract]   [Full Text] [Related]  

  • 20. Deceptive muscle invasive bladder cancer recurrence with benign biopsy foci after bladder sparing treatment.
    Xu C; Zeng S; Zhang Z; Song R; Ma C; Chen X; Sun Y
    Medicine (Baltimore); 2015 Jun; 94(22):e898. PubMed ID: 26039120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.